<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="preprint">
<?all-math-mml yes?>
<?use-mml?>
<?origin ukpmcpa?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">bioRxiv</journal-id>
<journal-title-group>
<journal-title>bioRxiv : the preprint server for biology</journal-title>
</journal-title-group>
<issn pub-type="ppub"/>
</journal-meta>
<article-meta>
<article-id pub-id-type="manuscript">EMS141159</article-id>
<article-id pub-id-type="doi">10.1101/2021.12.16.472920</article-id>
<article-id pub-id-type="archive">PPR433931</article-id>
<article-version article-version-type="publisher-id">1</article-version>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Amyloidogenesis of SARS-CoV-2 Spike Protein</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Nyström</surname>
<given-names>Sofie</given-names>
</name>
<xref ref-type="corresp" rid="CR1">*</xref>
<xref ref-type="fn" rid="FN1">‡</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hammarström</surname>
<given-names>Per</given-names>
</name>
<xref ref-type="corresp" rid="CR1">*</xref>
<xref ref-type="fn" rid="FN1">‡</xref>
</contrib>
<aff id="A1">Dept of Physics, Chemistry and Biology, Linköping University, Linköping, Sweden</aff>
</contrib-group>
<author-notes>
<corresp id="CR1">
<label>*</label>Corresponding Authors Sofie Nyström <email>sofie.nystrom@liu.se</email>, Per Hammarström, <email>per.hammarstrom@liu.se</email>
</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>07</day>
<month>02</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="preprint">
<day>17</day>
<month>12</month>
<year>2021</year>
</pub-date>
<permissions>
<ali:free_to_read/>
<license>
<ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
<license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p>
</license>
</permissions>
<abstract>
<p id="P1">SARS-CoV-2 infection is associated with a surprising number of morbidities. Uncanny similarities with amyloid-disease associated blood coagulation and fibrinolytic disturbances together with neurologic and cardiac problems led us to investigate the amyloidogenicity of the SARS-CoV-2 Spike protein (S-protein). Amyloid fibril assays of peptide library mixtures and theoretical predictions identified seven amyloidogenic sequences within the S-protein. All seven peptides in isolation formed aggregates during incubation at 37°C. Three 20-amino acid long synthetic Spike peptides (sequence 191-210, 599-618, 1165-1184) fulfilled three amyloid fibril criteria: nu-cleation dependent polymerization kinetics by ThT, Congo red positivity and ultrastructural fibrillar morphology. Full-length folded S-protein did not form amyloid fibrils, but amyloid-like fibrils with evident branching were formed during 24 hours of S-protein co-incubation with the protease neutrophil elastase (NE) in vitro. NE efficiently cleaved S-protein rendering exposure of amyloidogenic segments and accumulation of the peptide 193-202, part of the most amyloidogenic synthetic Spike peptide. NE is overexpressed at inflamed sites of viral infection and at vaccine injection sites. Our data propose a molecular mechanism for amyloidogenesis of SARS-CoV-2 S-protein in humans facilitated by endoproteolysis. The potential implications of S-protein amyloidogenesis in COVID-19 disease associated pathogenesis and consequences following S-protein based vaccines should be addressed in understanding the disease, long COVID-19, and vaccine side effects.</p>
</abstract>
</article-meta>
</front>
<body>
<p id="P2">The SARS-CoV-2 pandemic has severely impacted the world and official numbers state that over 270 million people have been infected (Dec 2021), but unrecorded cases are likely significantly higher. Corona viruses use the surface spike protein (S-protein) to attach to human cells. The S-protein is a homotrimer and each subunit of SARS-CoV-2 S-protein comprise 1273 amino acids. Four common corona viruses; OC43, 229E, NL63, HKU1 infect humans and colonize the respiratory tract. Recently emerged SARS, MERS and since 2019 also SARS-CoV-2, render severe disease. Although corona virus infections are common, it has not before COVID-19 been reports of such a wide distribution of complex symptoms involving other organs than the respiratory tract. Blood clotting, heart failure, peripheral neuropathy and CNS disorders are severe symptoms out of many reported. What could be the basis for this pathogenesis? Amyloidosis manifests as systemic and localized disorders with many overlapping phenotypes with reported COVID-19 symptoms. We therefore hypothesized on a potential molecular link. We were inspired by previous hypotheses about human and viral protein amyloids and interactions between them [<xref ref-type="bibr" rid="R1">1</xref>–<xref ref-type="bibr" rid="R3">3</xref>], in particular SARS-CoV spike proteins [<xref ref-type="bibr" rid="R4">4</xref>–<xref ref-type="bibr" rid="R6">6</xref>]. We asked the question if SARS-CoV-2 S-protein is amyloidogenic?</p>
<p id="P3">Motivated by Zhang et al 2018 [<xref ref-type="bibr" rid="R5">5</xref>] we first obtained a pool library of spike peptides, intended for antibody screening. The library comprised 316 peptides (delivered in two subpools of 158 peptides each) derived from a peptide scan (15-mers with 11 AA overlap, Supporting Inf. 2) through the entire SARS-CoV-2 S-protein (Protein ID: P0DTC2). The library was assayed for <italic>in vitro</italic> amyloid fibril formation. Fibrils were formed in both peptide subpools (Supporting Inf. 1 and <xref ref-type="supplementary-material" rid="SD1">SFig. 1</xref>). Encouraged by the results we moved on to generate 20 AA peptide sequences from the full-length SARS-CoV-2 S-protein. We aimed to address the most amyloidogenic sequences and used the WALTZ (<ext-link ext-link-type="uri" xlink:href="https://waltz.switchlab.org/">https://waltz.switchlab.org/</ext-link>) prediction algorithm [<xref ref-type="bibr" rid="R7">7</xref>] to identify such segments (<xref ref-type="table" rid="T1">Table 1</xref>).</p>
<p id="P4">The seven amyloidogenic sequences were distributed over the entire S-protein and are named according to the starting position of the S-protein (<xref ref-type="fig" rid="F1">Fig. 1</xref>). All but one (Spike362) of the predicted sequences are in beta-sheet conformation in the cryo-EM structure of SARS-CoV-2 S in its closed state [<xref ref-type="bibr" rid="R8">8</xref>].</p>
<p id="P5">The membrane spanning C-terminal part of the protein (Spike1165) is not included in the structure. Results from Alpha fold 2 [<xref ref-type="bibr" rid="R9">9</xref>] on the selected peptides indicate that three peptides; Spike259, Spike362 and Spike689, that are in β-strand conformation in the full-length protein are in helical conformation as free peptides (<xref ref-type="fig" rid="F1">Fig. 1B</xref>). One of the peptides (Spike599) was predicted by Alpha fold 2 to be random coil and the membrane spanning part was predicted to be an α-helix. Note that the sequences of Spike362 and Spike689 have been N-terminally modified with solubilizing sequences to enable production. Alpha fold 2 was performed on the sequences in <xref ref-type="table" rid="T1">Table 1</xref> (<xref ref-type="fig" rid="F1">Fig. 1B</xref>).</p>
<p id="P6">Lyophilized peptides were solubilized in hexa-fluoroisopropanol (HFIP) and were diluted in PBS-buffer (pH 7.5) to a final peptide concentration of 0.1 mg/ml (10% HFIP) and monitored for <italic>in vitro</italic> amyloid fibril formation kinetics using ThT, Congo red birefringence (CR) and negative stain transmission electron microscopy (TEM). Fibrils were formed within a few hours from most of the synthetic peptides by at least one but not all assays (<xref ref-type="table" rid="T1">Table 1</xref>, <xref ref-type="fig" rid="F2">Fig. 2</xref>). Spike191, Spike532 and Spike1165 fulfilled all our amyloid criteria: sigmoidal ThT kinetics, Congophilicity and fibrillar ultrastructure (<xref ref-type="fig" rid="F2">Fig. 2</xref>, <xref ref-type="table" rid="T1">Table 1</xref>). In particular, Spike191 formed exceptionally well-ordered fibrils (<xref ref-type="fig" rid="F2">Fig. 2C</xref>, <xref ref-type="fig" rid="F3">Fig. 3C</xref>).</p>
<p id="P7">The synthetic peptides were also prepared as a mixture of all seven peptides with a final concentration of 0.1 mg/ml of total peptide (concentration of each peptide ~0.014 mg/ml). The mixture of peptides resulted in amyloid fibril formation with sigmoidal ThT kinetics suggesting a nucleation dependent mechanism (<xref ref-type="fig" rid="F3">Fig. 3A</xref>). The fibril morphology from the mixture (<xref ref-type="fig" rid="F3">Fig. 3B</xref>) most closely resembled that of fibrils composed of the well-ordered Spike191 (cf. <xref ref-type="fig" rid="F3">Fig 3B; Fig. 3C</xref>), suggesting that this peptide is dominating the fibril structures in the mixture</p>
<p id="P8">What would be a plausible mechanism for S-protein fibril formation in a SARS-CoV-2 infected patient? SARS-CoV-2 S-protein is fairly stable (T<sub>m</sub> &gt;50 °C) [<xref ref-type="bibr" rid="R10">10</xref>] (see below) and would not readily denature spontaneously. Also, such a large protein with complex fold will not easily misfold into an amyloid state. However, proteolysis is an obvious candidate mechanism.</p>
<p id="P9">Endoproteolysis of precursor proteins is a well-known molecular initiation mechanism in several amyloidoses notably Alzheimer’s disease (AβPP), British and Danish dementia (ABri/ADan), and Finnish familial amyloidosis (AGel). Proteolysis of the full-length protein is also evident in many other amyloid disease deposits from ATTR, ALys, AA, ASem1 [<xref ref-type="bibr" rid="R11">11</xref>, <xref ref-type="bibr" rid="R12">12</xref>]. SARS-CoV-2 S-protein is proteolyzed during infection by host furin-like enzymes and by serine proteases such as the transmembrane protease, serine 2 (TMPRSS2), at the cell surface [<xref ref-type="bibr" rid="R13">13</xref>]. S-protein is further proteolyzed during inflammation. Neutrophils are the dominating class of leucocytes and are one of the first responders during acute inflammation. Neutrophils are recruited to the bronchoalveolar space of patients infected with a range of different respiratory viruses, including SARS-CoV-2 [<xref ref-type="bibr" rid="R14">14</xref>]. Neutrophils act both by phagocytosis of opsonized pathogens and by extracellular release of enzymes such as neutrophil elastase (NE). NE is a serine protease coupled to obstructive lung diseases such as cystic fibrosis, chronic obstructive pulmonary disease (COPD) [<xref ref-type="bibr" rid="R15">15</xref>] and alpha-1-antitrypsin deficiency [<xref ref-type="bibr" rid="R16">16</xref>]. The amino acid sequence of SARS-CoV-2 S-protein was tested with in silico proteolytic cleavage by NE using Expasy Peptide cutter. One of the resulting peptides, Spike193-212, was closely matching peptide Spike191, only frame shifted by 2 amino acids (Supporting information 3) implying a testable hypothesis.</p>
<p id="P10">We therefore subjected full-length SARS-CoV-2 S-protein to NE cleavage <italic>in vitro.</italic> We first determined that the S-protein was folded by thermal unfolding experiments by differential scanning fluorimetry (DSF) (<xref ref-type="fig" rid="F4">Fig. 4</xref>, <xref ref-type="supplementary-material" rid="SD1">SFig. 3</xref>).</p>
<p id="P11">S-protein showed a complex unfolding trajectory with multiple transitions around 45-65 °C, and a major unfolding transition with a midpoint of thermal denaturation (T<sub>m</sub>) 79 °C (<xref ref-type="fig" rid="F4">Fig. 4A</xref>, <xref ref-type="supplementary-material" rid="SD1">SFig 3A</xref>), similar to that reported for another full-length S-protein construct [<xref ref-type="bibr" rid="R17">17</xref>]. S-protein refolded upon lowering the temperature albeit with a non-cooperative refolding transition (<xref ref-type="fig" rid="F4">Fig. 4A</xref>). NE unfolded irreversibly with at Tm of 59 °C (<xref ref-type="fig" rid="F4">Fig. 4B</xref>). The incubated S-protein + NE only showed an obvious transition for NE and did not refold upon lowering the temperature suggesting that S-protein had been cleaved by NE (<xref ref-type="fig" rid="F4">Fig. 4C</xref>). We verified digestion by mass spectrometry where only the S-protein + NE experiment revealed peptide peaks (<xref ref-type="fig" rid="F4">Fig. 4D-F</xref>). Most importantly we discovered amyloid-like fibril formation dependent on this proteolytic cleavage by TEM. Neither NE nor SARS-CoV-2 S-protein incubated alone formed fibrils (<xref ref-type="fig" rid="F4">Fig. 4G-H</xref>). Fibrils were only found after co-incubation of the two proteins (<xref ref-type="fig" rid="F4">Fig. 4I</xref>). The fibrils had an unusual morphology with evident branching (<xref ref-type="fig" rid="F4">Fig. 4I</xref>). This morphology suggests involvement of proteolytically nicked S-protein within the fibril rendering nodes for branching of different amyloidogenic sequences (<xref ref-type="fig" rid="F4">Fig. 4I</xref>, <xref ref-type="supplementary-material" rid="SD1">SFig. 4</xref>). To understand how NE cleaved S-protein we performed LC-MS/MS analysis of peptides formed after 1 min and 6 h of digestion at 2:1 excess of NE over S-protein. We mapped 98 identified NE cleavage peptides (<xref ref-type="supplementary-material" rid="SD1">STable 1</xref>) on the S-protein structure and classed these into three groups: i) formed after 1 min (<xref ref-type="fig" rid="F5">Fig. 5A, B</xref>), ii) formed after 1 min and still present after 6 h (<xref ref-type="fig" rid="F5">Fig. 5A, C</xref>), and iii) only present after 6 h (<xref ref-type="fig" rid="F5">Fig. 5A, D</xref>). Initial cleavage and further digestion (group i) occurred mainly within the S2 domain with abundant cleavage of the HR domains and in the C-terminal part of S1. NTD and RBD were much less affected (<xref ref-type="fig" rid="F5">Fig. 5A</xref>). Three persistent peptides formed after initial cleavage (group ii) originated from NTD and RBD. Several peptides only formed after 6 h of incubation (group iii). Strikingly the peptide from the segment 193-202 (FKNIDGYFKI, included in Spike191) was part of this group and was highly abundant after 6 h (<xref ref-type="supplementary-material" rid="SD1">STable 2</xref>). Compared to the amyloidogenic sequences three peptides containing segments from these were formed as free peptides (Spike191, Spike259, Spike1165) still present after 6 hours of co-incubation, two were digested early and disappeared (Spike532, Spike689), and two were likely still resident in the parent nicked S-protein (Spike362, Spike599). Hence the observed formed branched fibrils is likely composed of a mix of fibrils initiated by an amyloidogenic peptide seed recruiting nicked S-protein for elongation and branching.</p>
<p id="P12">What are the implications of our findings? COVID-19 pathogenesis is multifactorial and complex [<xref ref-type="bibr" rid="R18">18</xref>]. Severe COVID-19 include acute respiratory distress syndrome (ARDS) from severe innate immune system inflammatory reactions resulting in lung damage [<xref ref-type="bibr" rid="R19">19</xref>]; Cytokine storm [<xref ref-type="bibr" rid="R20">20</xref>]; Heart damage, including inflammation of the heart muscle; Kidney damage; Neurological damage; Damage to the circulatory system resulting in poor blood flow; Long-COVID symptoms include persistent emotional illness and other mental health conditions resembling neurodegenerative diseases [<xref ref-type="bibr" rid="R18">18</xref>].</p>
<p id="P13">It has been proposed that severe inflammatory disease including ARDS in combination with SARS-CoV-2 protein aggregation might induce systemic AA amyloidosis [<xref ref-type="bibr" rid="R21">21</xref>]. Neurotropic colonization and cross-seeding of S-protein amyloid fibrils to induce aggregation of human endogenous proteins has been discussed in the context of neurodegeneration [<xref ref-type="bibr" rid="R4">4</xref>]. Notably, blood clotting associated with extracellular amyloidotic fibrillar aggregates in the blood stream have been reported in affected COVID-19 patients [<xref ref-type="bibr" rid="R22">22</xref>]. Hypercoagulation and impaired fibrinolysis were demonstrated in experimentally S-protein spiked blood plasma from healthy donors [<xref ref-type="bibr" rid="R22">22</xref>]. Similarly, amyloidosis is associated with cerebral amyloid angiopathy, blood coagulation disruption, fibrinolytic disturbance [<xref ref-type="bibr" rid="R23">23</xref>, <xref ref-type="bibr" rid="R24">24</xref>] and FXII Kallikrein/Kinin activation and thromboinflammation [<xref ref-type="bibr" rid="R25">25</xref>], suggesting potential links between amyloidogenesis of S-protein and COVID-19 phenotypes.</p>
<p id="P14">In conclusion, we herein proposed a rather simple molecular mechanism for how SARS-CoV-2 S-protein endoproteolysis by NE can render exceptionally amyloidogenic S-peptides such as segment 193202, and exposure of multiple amyloidogenic segments in proteolytically nicked S-protein. It is possible that other amyloidogenic peptides and S-protein nicked by other proteases could be involved. We found that all common coronaviruses infecting humans contain amyloidogenic sequences (<xref ref-type="supplementary-material" rid="SD1">SFig. 5A</xref>). Nonetheless, the magnitude of the diverse COVID-19 symptoms was not previously reported. The segment 193-212 is unique for and SARS-CoV-2 (<xref ref-type="supplementary-material" rid="SD1">SFig. 5B</xref>), which in combination with acute inflammation could explain the putative COVID-19 associated amyloidosis.</p>
<p id="P15">Furthermore, over the course of the year 2021 over 8 billion doses of COVID-19 vaccines have been administered worldwide. Most doses have provided SARS-CoV-2 S-protein as main antigen. A recent case report describes the serendipitous discovery of amyloid formation in a human patient locally at the site of vaccination and in a proximal lymph node within 24 hours of the first dose of mRNA vaccine coding for S-protein [<xref ref-type="bibr" rid="R26">26</xref>]. Neutrophil recruitment and activation at the site of vaccination is expected. The localized amyloid was detected by the Aβ amyloid PET tracer <sup>18</sup>F-Florbetaben also known to bind to AL, AA and ATTR cardiac amyloid fibrils. The reactant alleged amyloidogenic protein in the vaccinated patient was not identified. We tested the fluorescent amyloid ligands CN-PiB (fluorescent benzothiazole analogue of Pittsburgh compound B) and DF-9 (fluorescent stilbene analogue of Florbetaben) and found strong fluorescence response towards Spike191 fibrils <italic>in vitro</italic> (<xref ref-type="supplementary-material" rid="SD1">SFig. 6</xref>), supporting the possibility that vaccine induced S-protein derived amyloid deposition was detected in the human PET imaging case study [<xref ref-type="bibr" rid="R26">26</xref>].</p>
<p id="P16">If the herein proposed mechanism for S-protein amyloid formation is associated with reported cardiac,- blood,- and nervous system disorders in certain vaccinated individuals [<xref ref-type="bibr" rid="R27">27</xref>] is not known, neither are the long-term consequences, but is strongly recommended to be investigated in this context.</p>
<sec id="S1">
<title>Abbreviations</title>
<glossary>
<def-list>
<def-item>
<term>CNS</term>
<def>
<p id="P17">central nervous system</p>
</def>
</def-item>
<def-item>
<term>SARS-CoV-2</term>
<def>
<p id="P18">Severe Acute Respiratory Syndrome Coronavirus-2</p>
</def>
</def-item>
<def-item>
<term>S-protein</term>
<def>
<p id="P19">Spike protein</p>
</def>
</def-item>
<def-item>
<term>ThT</term>
<def>
<p id="P20">Thioflavin T</p>
</def>
</def-item>
<def-item>
<term>CN-PiB</term>
<def>
<p id="P21">Cyano-Pittsburgh compound B</p>
</def>
</def-item>
<def-item>
<term>TEM</term>
<def>
<p id="P22">transmission electron microscopy</p>
</def>
</def-item>
<def-item>
<term>DSF</term>
<def>
<p id="P23">Differential scanning fluorimetry</p>
</def>
</def-item>
</def-list>
</glossary>
</sec>
<sec sec-type="supplementary-material" id="SM">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="SD1">
<label>Supplemental Info Figs Tables Nystrom Hammarstrom</label>
<media xlink:href="EMS141159-supplement-Supplemental_Info_Figs_Tables_Nystrom_Hammarstrom.pdf" mimetype="application" mime-subtype="pdf" id="N66127" position="anchor"/>
</supplementary-material>
</sec>
</body>
<back>
<ack id="S2">
<title>Acknowledgment</title>
<p>We thank Björn Wallner for generating Alpha fold 2 folding predictions of the synthetic peptides, Xiongyu Wu for synthesis of CN-PiB, and Jun Zhang for synthesis of DF-9. We acknowledge the use Li U core-facilities ProLinC, Medical Faculty Microscopy and Proteomics core especially Maria Turkina for collection of experimental data.</p>
<sec id="S3">
<title>Funding Sources</title>
<p>This research was financed by The Swedish Research Council grant #2019-04405).</p>
</sec>
</ack>
<fn-group>
<fn id="FN1" fn-type="con">
<label>‡</label>
<p id="P24">Author Contributions</p>
<p id="P25">The research was performed, and manuscript was written with equal contributions of both authors. Both authors have given approval to the final version of the manuscript.</p>
</fn>
</fn-group>
<ref-list>
<ref id="R1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Munch</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>Semen-derived amyloid fibrils drastically enhance HIV infection</article-title>
<source>Cell</source>
<year>2007</year>
<volume>131</volume>
<issue>6</issue>
<fpage>1059</fpage>
<lpage>71</lpage>
</element-citation>
</ref>
<ref id="R2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tayeb-Fligelman</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group>
<article-title>Inhibition of amyloid formation of the Nucleoprotein of SARS-CoV-2</article-title>
<source>bioRxiv</source>
<year>2021</year>
</element-citation>
</ref>
<ref id="R3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Michiels</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Rousseau</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Schymkowitz</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Mechanisms and therapeutic potential of interactions between human amyloids and viruses</article-title>
<source>Cell Mol Life Sci</source>
<year>2021</year>
<volume>78</volume>
<issue>6</issue>
<fpage>2485</fpage>
<lpage>2501</lpage>
</element-citation>
</ref>
<ref id="R4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tavassoly</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Safavi</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Tavassoly</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Seeding Brain Protein Aggregation by SARS-CoV-2 as a Possible Long-Term Complication of COVID-19 Infection</article-title>
<source>ACS Chem Neurosci</source>
<year>2020</year>
<volume>11</volume>
<issue>22</issue>
<fpage>3704</fpage>
<lpage>3706</lpage>
</element-citation>
</ref>
<ref id="R5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>SM</given-names>
</name>
<etal/>
</person-group>
<article-title>Identification and application of self-binding zipper-like sequences in SARS-CoV spike protein</article-title>
<source>Int J Biochem Cell Biol</source>
<year>2018</year>
<volume>101</volume>
<fpage>103</fpage>
<lpage>112</lpage>
</element-citation>
</ref>
<ref id="R6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Idrees</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>SARS-CoV-2 spike protein interactions with amyloidogenic proteins: Potential clues to neurodegeneration</article-title>
<source>Biochem Biophys Res Commun</source>
<year>2021</year>
<volume>554</volume>
<fpage>94</fpage>
<lpage>98</lpage>
</element-citation>
</ref>
<ref id="R7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maurer-Stroh</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>Exploring the sequence determinants of amyloid structure using position-specific scoring matrices</article-title>
<source>Nat Methods</source>
<year>2010</year>
<volume>7</volume>
<issue>3</issue>
<fpage>237</fpage>
<lpage>42</lpage>
</element-citation>
</ref>
<ref id="R8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<etal/>
</person-group>
<article-title>Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein</article-title>
<source>Cell</source>
<year>2020</year>
<volume>181</volume>
<issue>2</issue>
<fpage>281</fpage>
<lpage>292</lpage>
<elocation-id>e6</elocation-id>
</element-citation>
</ref>
<ref id="R9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jumper</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>Highly accurate protein structure prediction with AlphaFold</article-title>
<source>Nature</source>
<year>2021</year>
<volume>596</volume>
<issue>7873</issue>
<fpage>583</fpage>
<lpage>589</lpage>
</element-citation>
</ref>
<ref id="R10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Upadhyay</surname>
<given-names>V</given-names>
</name>
<etal/>
</person-group>
<article-title>Receptor binding, immune escape, and protein stability direct the natural selection of SARS-CoV-2 variants</article-title>
<source>J Biol Chem</source>
<year>2021</year>
<volume>297</volume>
<issue>4</issue>
<elocation-id>101208</elocation-id>
</element-citation>
</ref>
<ref id="R11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benson</surname>
<given-names>MD</given-names>
</name>
<etal/>
</person-group>
<article-title>Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee</article-title>
<source>Amyloid</source>
<year>2020</year>
<volume>27</volume>
<issue>4</issue>
<fpage>217</fpage>
<lpage>222</lpage>
</element-citation>
</ref>
<ref id="R12">
<label>12</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Sipe</surname>
<given-names>JD</given-names>
</name>
</person-group>
<source>Amyloid proteins : the beta sheet conformation and disease</source>
<year>2005</year>
<publisher-loc>Weinheim, Chichester</publisher-loc>
<publisher-name>Wiley-VCH, John Wiley</publisher-name>
</element-citation>
</ref>
<ref id="R13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peacock</surname>
<given-names>TP</given-names>
</name>
<etal/>
</person-group>
<article-title>The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets</article-title>
<source>Nat Microbiol</source>
<year>2021</year>
<volume>6</volume>
<issue>7</issue>
<fpage>899</fpage>
<lpage>909</lpage>
</element-citation>
</ref>
<ref id="R14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johansson</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kirsebom</surname>
<given-names>FCM</given-names>
</name>
</person-group>
<article-title>Neutrophils in respiratory viral infections</article-title>
<source>Mucosal Immunol</source>
<year>2021</year>
<volume>14</volume>
<issue>4</issue>
<fpage>815</fpage>
<lpage>827</lpage>
</element-citation>
</ref>
<ref id="R15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pandey</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>De</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mishra</surname>
<given-names>PK</given-names>
</name>
</person-group>
<article-title>Role of Proteases in Chronic Obstructive Pulmonary Disease</article-title>
<source>Front Pharmacol</source>
<year>2017</year>
<volume>8</volume>
<fpage>512</fpage>
</element-citation>
</ref>
<ref id="R16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Strnad</surname>
<given-names>P</given-names>
</name>
<name>
<surname>McElvaney</surname>
<given-names>NG</given-names>
</name>
<name>
<surname>Lomas</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>Alpha1-Antitrypsin Deficiency</article-title>
<source>N Engl J Med</source>
<year>2020</year>
<volume>382</volume>
<issue>15</issue>
<fpage>1443</fpage>
<lpage>1455</lpage>
</element-citation>
</ref>
<ref id="R17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Edwards</surname>
<given-names>RJ</given-names>
</name>
<etal/>
</person-group>
<article-title>Cold sensitivity of the SARS-CoV-2 spike ectodomain</article-title>
<source>Nat Struct Mol Biol</source>
<year>2021</year>
<volume>28</volume>
<issue>2</issue>
<fpage>128</fpage>
<lpage>131</lpage>
</element-citation>
</ref>
<ref id="R18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>
<article-title>6-month consequences of COVID-19 in patients discharged from hospital: a cohort study</article-title>
<source>Lancet</source>
<year>2021</year>
<volume>397</volume>
<issue>10270</issue>
<fpage>220</fpage>
<lpage>232</lpage>
</element-citation>
</ref>
<ref id="R19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lipcsey</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>The Outcome of Critically Ill COVID-19 Patients Is Linked to Thromboinflammation Dominated by the Kallikrein/Kinin System</article-title>
<source>Front Immunol</source>
<year>2021</year>
<volume>12</volume>
<elocation-id>627579</elocation-id>
</element-citation>
</ref>
<ref id="R20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname>
<given-names>YM</given-names>
</name>
<etal/>
</person-group>
<article-title>Cytokine storm syndrome in coronavirus disease 2019: A narrative review</article-title>
<source>J Intern Med</source>
<year>2021</year>
<volume>289</volume>
<issue>2</issue>
<fpage>147</fpage>
<lpage>161</lpage>
</element-citation>
</ref>
<ref id="R21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sinha</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Thakur</surname>
<given-names>AK</given-names>
</name>
</person-group>
<article-title>Likelihood of amyloid formation in COVID-19-induced ARDS</article-title>
<source>Trends Microbiol</source>
<year>2021</year>
<volume>29</volume>
<issue>11</issue>
<fpage>967</fpage>
<lpage>969</lpage>
</element-citation>
</ref>
<ref id="R22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grobbelaar</surname>
<given-names>LM</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: implications for microclot formation in COVID-19</article-title>
<source>Biosci Rep</source>
<year>2021</year>
<volume>41</volume>
<issue>8</issue>
</element-citation>
</ref>
<ref id="R23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hammarstrom</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>The bloody path of amyloids and prions</article-title>
<source>J Thromb Haemost</source>
<year>2007</year>
<volume>5</volume>
<issue>6</issue>
<fpage>1136</fpage>
<lpage>8</lpage>
</element-citation>
</ref>
<ref id="R24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bouma</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>
<article-title>Increased plasmin-alpha2-antiplasmin levels indicate activation of the fibrinolytic system in systemic amyloidoses</article-title>
<source>J Thromb Haemost</source>
<year>2007</year>
<volume>5</volume>
<issue>6</issue>
<fpage>1139</fpage>
<lpage>42</lpage>
</element-citation>
</ref>
<ref id="R25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maas</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>
<article-title>Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation</article-title>
<source>J Clin Invest</source>
<year>2008</year>
<volume>118</volume>
<issue>9</issue>
<fpage>3208</fpage>
<lpage>18</lpage>
</element-citation>
</ref>
<ref id="R26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laudicella</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>
<article-title>Subcutaneous Uptake on [18F]Florbetaben PET/CT: a Case Report of Possible Amyloid-Beta Immune-Reactivity After COVID-19 Vaccination</article-title>
<source>SN Compr Clin Med</source>
<year>2021</year>
<fpage>1</fpage>
<lpage>3</lpage>
</element-citation>
</ref>
<ref id="R27">
<label>27</label>
<element-citation publication-type="web">
<source>COVID-19 mRNA Pfizer-BioNTech Vaccine Analysis Print</source>
<year>2021</year>
<month>November</month>
<day>17</day>
<date-in-citation>cited 2021 29 November 2021</date-in-citation>
<comment>Available from: <ext-link ext-link-type="uri" xlink:href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1036445/COVID-19_mRNA_Pfizer-BioNTech_Vaccine_Analysis_Print_DLP_17.11.2021.pdf">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1036445/COVID-19_mRNA_Pfizer-BioNTech_Vaccine_Analysis_Print_DLP_17.11.2021.pdf</ext-link>
</comment>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p>A. The structure of one protomer of the trimeric SARS-CoV-2 S-protein in its closed state, PDB code: 6VXX [<xref ref-type="bibr" rid="R8">8</xref>] with the predicted full sequence of the amyloidogenic peptides highlighted in the same colors as the predictions in <xref ref-type="table" rid="T1">Table 1</xref>. B. Conformation of peptides within the folded S-protein in comparison with Alpha Fold 2 models of the synthetic peptides (<xref ref-type="table" rid="T1">Table 1</xref>).</p>
</caption>
<graphic xlink:href="EMS141159-f001"/>
</fig>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<title>Amyloid fibril assays of SARS-CoV-2 S peptides (0.1 mg/ml).</title>
<p>A. Fibril formation kinetics monitored by ThT fluorescence. B. Congo red staining microscopy with open and crossed polarizers. C. Ultrastructure by negative stain TEM.</p>
</caption>
<graphic xlink:href="EMS141159-f002"/>
</fig>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<title>Amyloid fibrillation of 7 mixed SARS-CoV-2 S-peptides (total concentration 0.1 mg/ml).</title>
<p>A. Fibril formation kinetics monitored by ThT fluorescence. B. Fibrillar structures by negative stain TEM. C. Fibrillar structures by negative stain TEM of Spike191 resembling the mix.</p>
</caption>
<graphic xlink:href="EMS141159-f003"/>
</fig>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption>
<title>S-protein proteolysis by NE renders amyloid-like fibrils.</title>
<p>A. Thermostability of the SARS-CoV-2 S-protein, B. NE and C. S-protein + NE, measured by DSF. The dashed line in C is the mathematical sum of S-protein and NE respectively from A and B which does not fit the experimental data, supporting cleavage of S-protein by NE. MALDI-ToF spectra of C18 isolated peptides of D. S-protein, E. NE, and F. S-protein + NE (6 h, 37 °C). TEM micrographs of G. S-protein alone depicting the expected trimers [<xref ref-type="bibr" rid="R17">17</xref>] H. NE alone, and I. S-protein and NE co-incubated at pH 8.4 for 24 h, 37 °C. Clusters of amyloidlike branched fibrils were formed in the co-incubation experiment in I.</p>
</caption>
<graphic xlink:href="EMS141159-f004"/>
</fig>
<fig id="F5" position="float">
<label>Figure 5</label>
<caption>
<title>NE cleavage sites within full-length folded S-protein.</title>
<p>A. Overall map of peptides identified by LC-MS/MS in correlation to the amyloidogenic Spike peptides (c.f. <xref ref-type="fig" rid="F1">Fig. 1</xref> and <xref ref-type="table" rid="T1">Table 1</xref>) and the S-protein domain structure. Arrows indicate the limits of the cryo-EM structure 27-1146. After i) 1 min (red), ii) 1 min and still persistent at 6 h (magenta), iii) only present after 6 h of incubation (blue). B-D. the same color code for cleaved peptide group i-iii mapped onto the protomer Cryo-EM S-protein structure PDB code 6VXX.</p>
</caption>
<graphic xlink:href="EMS141159-f005"/>
</fig>
<table-wrap id="T1" position="float" orientation="portrait">
<label>Table 1</label>
<caption>
<title>Amino acid sequences and properties of synthetic SARS-CoV-2 S-protein peptides</title>
</caption>
<table frame="box" rules="all">
<thead>
<tr>
<th align="left" valign="top" style="background-color:#aeaaaa">Peptide</th>
<th align="left" valign="top" style="background-color:#aeaaaa">Amino acid sequence*</th>
<th align="left" valign="top" style="background-color:#aeaaaa">MW (Da)**</th>
<th align="center" valign="top" style="background-color:#aeaaaa">pI</th>
<th align="center" valign="top" style="background-color:#aeaaaa">ThT kin</th>
<th align="center" valign="top" style="background-color:#aeaaaa">Congo Red</th>
<th align="left" valign="top" style="background-color:#aeaaaa">Ultrastructure</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">Spike191</td>
<td align="left" valign="top">FVFKNID<styled-content style="color:#ff0000">GYFKIY</styled-content>SKHTPIN</td>
<td align="center" valign="top">2431</td>
<td align="center" valign="top">9.4</td>
<td align="center" valign="top">+</td>
<td align="center" valign="top">+</td>
<td align="left" valign="top">fibril</td>
</tr>
<tr>
<td align="left" valign="top">Spike259</td>
<td align="left" valign="top">WTAG<styled-content style="color:#53ff53">AAAYYVGYL</styled-content>QPRTFLLK</td>
<td align="center" valign="top">2389</td>
<td align="center" valign="top">9.5</td>
<td align="center" valign="top">-</td>
<td align="center" valign="top">+</td>
<td align="left" valign="top">fibril</td>
</tr>
<tr>
<td align="left" valign="top">Spike362</td>
<td align="left" valign="top">KKKGGG<styled-content style="color:#0065ff">YSVLYNSA</styled-content>SFSTFK</td>
<td align="center" valign="top">2169</td>
<td align="center" valign="top">10.0</td>
<td align="center" valign="top">-</td>
<td align="center" valign="top">+</td>
<td align="left" valign="top">amorphous</td>
</tr>
<tr>
<td align="left" valign="top">Spike532</td>
<td align="left" valign="top">NLVKN<styled-content style="color:#68ffff">KCVNFNFN</styled-content>GLTGTGV</td>
<td align="center" valign="top">2139</td>
<td align="center" valign="top">9.3</td>
<td align="center" valign="top">+</td>
<td align="center" valign="top">+</td>
<td align="left" valign="top">amorphous</td>
</tr>
<tr>
<td align="left" valign="top">Spike599</td>
<td align="left" valign="top">GTNTSNQ<styled-content style="color:#ff00ff">VAVLYQ</styled-content>D0VNCTEV</td>
<td align="center" valign="top">2155</td>
<td align="center" valign="top">3.7</td>
<td align="center" valign="top">+</td>
<td align="center" valign="top">+</td>
<td align="left" valign="top">fibril</td>
</tr>
<tr>
<td align="left" valign="top">Spike689</td>
<td align="left" valign="top">KKKRSVA<styled-content style="color:#ff7439">SQSIIAYTM</styled-content>SLGA</td>
<td align="center" valign="top">2139</td>
<td align="center" valign="top">10.5</td>
<td align="center" valign="top">-</td>
<td align="center" valign="top">-</td>
<td align="left" valign="top">ribbons</td>
</tr>
<tr>
<td align="left" valign="top">Spike1165</td>
<td align="left" valign="top">LGDISGINA<styled-content style="color:#9a65ff">SVVNI</styled-content>QKEIDR</td>
<td align="center" valign="top">2141</td>
<td align="center" valign="top">4.6</td>
<td align="center" valign="top">+</td>
<td align="center" valign="top">+</td>
<td align="left" valign="top">fibril</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="TFN1">
<label>*</label>
<p id="P26">Residues assigned in color indicate the amyloidogenic segments as predicted by WALTZ. Highlighted in gray are non-native amino acids introduced for solubility. **Theoretical mass (Dalton). Mass spectra of peptides in <xref ref-type="supplementary-material" rid="SD1">SFig. 2</xref>.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
